Picard Medical (PMI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
A special meeting of stockholders will be held online to approve an amendment to the 2021 Equity Incentive Plan, increasing the share reserve to 18,000,000 and adding warrants as an award type.
The Board and Compensation Committee believe the amendment is vital for attracting, retaining, and incentivizing key personnel and aligning their interests with long-term stockholder value.
If the amendment is not approved, there will be insufficient shares for future awards, potentially requiring a shift to cash-based compensation.
Voting matters and shareholder proposals
The primary proposal is to amend the 2021 Equity Incentive Plan to increase the share reserve and include warrants as an award type.
The Board unanimously recommends voting FOR the proposal.
Only stockholders of record as of September 16, 2025, are entitled to vote.
Abstentions count as votes against; broker non-votes have no effect.
Board of directors and corporate governance
The Board has authority to administer the Amended Incentive Plan and may delegate certain powers to a committee or individual Board member.
The Board is responsible for recommending and overseeing the proposed plan amendment.
Latest events from Picard Medical
- Approval sought for major share increase and new issuances to enable financing and NYSE compliance.PMI
Proxy Filing19 Feb 2026 - Vote proposed to double authorized common stock, supporting future capital needs and flexibility.PMI
Proxy Filing19 Feb 2026 - Shareholders to vote on doubling authorized common stock to enable future growth and flexibility.PMI
Proxy Filing10 Feb 2026 - FDA-approved artificial heart maker registers 17M shares for resale amid ongoing losses and risks.PMI
Registration Filing4 Feb 2026 - Market leader advances total artificial heart tech, targeting global growth and next-gen innovation.PMI
H.C. Wainwright 27th Annual Global Investment Conference3 Feb 2026 - Resale of up to 17M shares may dilute holders as company seeks growth in artificial heart market.PMI
Registration Filing12 Jan 2026 - Vote to expand the equity plan and add warrants, supporting long-term talent retention.PMI
Proxy Filing2 Dec 2025 - FDA-approved artificial heart leader seeks IPO to fund R&D, China JV, and address liquidity.PMI
Registration Filing29 Nov 2025 - FDA-approved artificial heart leader seeks IPO to fund R&D and global expansion amid ongoing losses.PMI
Registration Filing29 Nov 2025